SG11201810901VA - Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid - Google Patents

Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid

Info

Publication number
SG11201810901VA
SG11201810901VA SG11201810901VA SG11201810901VA SG11201810901VA SG 11201810901V A SG11201810901V A SG 11201810901VA SG 11201810901V A SG11201810901V A SG 11201810901VA SG 11201810901V A SG11201810901V A SG 11201810901VA SG 11201810901V A SG11201810901V A SG 11201810901VA
Authority
SG
Singapore
Prior art keywords
compositions
aqueous solution
injectable aqueous
human glucagon
copolyamino acid
Prior art date
Application number
SG11201810901VA
Inventor
Alexandre Geissler
Ségolène LAAGE
Olivier Soula
David Duracher
Grégory Meiffren
Original Assignee
Adocia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1655221A external-priority patent/FR3052071B1/en
Priority claimed from FR1750221A external-priority patent/FR3061660B1/en
Application filed by Adocia filed Critical Adocia
Publication of SG11201810901VA publication Critical patent/SG11201810901VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPOSITIONS IN THE FORM OF AN INJECTABLE AQUEOUS SOLUTION, COMPRISING HUMAN GLUCAGON AND A STATISTICAL COPOLYAMINO ACID [000577] The invention thus relates to physically stable compositions in the form of an injectable aqueous solution, the pH of which is from 6.0 to 8.0, comprising at least: a) human glucagon, and b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, [000578] In an embodiment, the compositions according to the invention comprise, in addition, a gastrointestinal hormone.
SG11201810901VA 2016-06-07 2017-06-07 Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid SG11201810901VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1655221A FR3052071B1 (en) 2016-06-07 2016-06-07 COMPOSITIONS IN THE FORM OF AQUEOUS INJECTABLE SOLUTION COMPRISING GLUCAGON AND A CO-POLYAMINOACID
FR1750221A FR3061660B1 (en) 2017-01-10 2017-01-10 COMPOSITIONS IN THE FORM OF AN INJECTION AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID
PCT/EP2017/063887 WO2017211917A1 (en) 2016-06-07 2017-06-07 Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid

Publications (1)

Publication Number Publication Date
SG11201810901VA true SG11201810901VA (en) 2019-01-30

Family

ID=59021507

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201810939PA SG11201810939PA (en) 2016-06-07 2017-06-07 Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid
SG11201810901VA SG11201810901VA (en) 2016-06-07 2017-06-07 Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201810939PA SG11201810939PA (en) 2016-06-07 2017-06-07 Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid

Country Status (11)

Country Link
US (2) US10485851B2 (en)
EP (2) EP3463294B1 (en)
JP (2) JP2019521107A (en)
KR (2) KR20190026748A (en)
CN (2) CN109562064A (en)
AU (2) AU2017277589A1 (en)
BR (2) BR112018075259A2 (en)
CA (2) CA3026802A1 (en)
MX (2) MX2018015069A (en)
SG (2) SG11201810939PA (en)
WO (2) WO2017211917A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3083089A1 (en) * 2018-06-29 2020-01-03 Adocia PH 7 INJECTION SOLUTION COMPRISING AT LEAST ONE BASAL INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACID CARRYING CARBOXYLATES AND HYDROPHOBIC RADICALS
WO2019110837A1 (en) * 2017-12-07 2019-06-13 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
MA51017A (en) 2017-12-07 2021-03-17 Adocia COMPOSITIONS IN THE FORM OF AN AQUEOUS SOLUTION FOR INJECTION CONSISTING OF HUMAN GLUCAGON AND A CO-POLYAMINOACID
FR3083087A1 (en) * 2018-06-29 2020-01-03 Adocia COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINOACID
JP2021505605A (en) 2017-12-07 2021-02-18 アドシア An injectable solution having a pH of 7 containing at least one basal insulin having a pI of 5.8 to 8.5 and a copolyamino acid having a carboxylate charge and a hydrophobic radical.
FR3083086A1 (en) * 2018-06-29 2020-01-03 Adocia COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
WO2019110838A1 (en) * 2017-12-07 2019-06-13 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
WO2019115411A1 (en) * 2017-12-07 2019-06-20 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analogue and a copolyamino acid
CN111683675A (en) * 2017-12-07 2020-09-18 阿道恰公司 Compositions in the form of injectable aqueous solutions comprising human glucagon and a polyamino acid copolymer
JP2021505616A (en) 2017-12-07 2021-02-18 アドシア Composition in the form of an aqueous injectable solution containing amyrin, amyrin agonist receptor or amyrin analog and copolyamino acids
EP3740229A1 (en) 2017-12-07 2020-11-25 Adocia Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
EP3740195A1 (en) 2017-12-07 2020-11-25 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
CN108174843B (en) * 2018-01-24 2018-11-13 广州市进德生物科技有限公司 A kind of glucagon protective agent and its application
FR3084584B1 (en) * 2018-08-03 2020-11-06 Adocia SOLUTION FOR INJECTION AT PH 7 COMPRISING HUMAN GLUCAGON AND AN AMPHIPHILIC COMPOUND CARRIER OF HYDROPHOBIC RADICALS
EP4091625A1 (en) 2021-05-22 2022-11-23 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1202607A (en) * 1968-01-10 1970-08-19 Novo Terapeutisk Labor As Improvements in or relating to stable glucagon solutions and their preparation
DE69918070T2 (en) 1998-03-13 2005-08-25 Novo Nordisk A/S Stabilized, aqueous glucagon solutions containing detergents
FR2801226B1 (en) 1999-11-23 2002-01-25 Flamel Tech Sa COLLOIDAL SUSPENSION OF SUBMICRONIC PARTICLES FOR VECTORIZATION OF ACTIVE INGREDIENTS AND METHOD OF PREPARATION
FR2840614B1 (en) 2002-06-07 2004-08-27 Flamel Tech Sa POLYAMINOACIDS FUNCTIONALIZED BY ALPHA-TOCOPHEROL AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
FR2881140B1 (en) * 2005-01-27 2007-04-06 Flamel Technologies Sa COPOLYHYDROXYALKYLGLUTAMINES FUNCTIONALIZED BY HYDROPHOBIC GROUPS AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
FR2902007B1 (en) * 2006-06-09 2012-01-13 Flamel Tech Sa PHARMACEUTICAL FORMULATIONS FOR PROLONGED DELIVERY OF ACTIVE (S) PRINCIPLE (S) AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
FR2915683B1 (en) * 2007-05-03 2009-08-07 Flamel Technologies Sa SELF-PRECIPITANT PHARMACEUTICAL FORMULATIONS FOR MODIFIED RELEASE OF ACTIVE INGREDIENTS
US20110097386A1 (en) 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions
WO2011138802A1 (en) * 2010-05-07 2011-11-10 Sun Pharma Advanced Research Company Ltd., Injection solution
EP2635296B1 (en) 2010-11-03 2014-12-24 Arecor Limited Novel composition comprising glucagon
WO2013101749A1 (en) 2011-12-29 2013-07-04 Latitude Pharmaceuticals, Inc. Stabilized glucagon nanoemulsions
CN107583039A (en) * 2012-01-09 2018-01-16 阿道恰公司 PH is 7 and the Injectable solution at least containing the PI basal insulins for being 5.8 to 8.5 and substitution copolymerization (amino acid)
WO2014096440A2 (en) 2012-12-21 2014-06-26 Novozymes Biopharma Dk A/S Composition
WO2015095389A1 (en) 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions for drug administration
US9334316B2 (en) 2014-04-11 2016-05-10 Oregon Health & Science University Formulations comprising glucagon

Also Published As

Publication number Publication date
EP3463295A1 (en) 2019-04-10
AU2017277590A1 (en) 2019-01-24
EP3463294B1 (en) 2020-08-05
JP2019517560A (en) 2019-06-24
US10485851B2 (en) 2019-11-26
CA3026802A1 (en) 2017-12-14
EP3463294A1 (en) 2019-04-10
EP3463295B1 (en) 2020-08-05
CA3027238A1 (en) 2017-12-14
CN109562064A (en) 2019-04-02
JP2019521107A (en) 2019-07-25
MX2018015069A (en) 2019-05-09
US10383918B2 (en) 2019-08-20
WO2017211918A1 (en) 2017-12-14
SG11201810939PA (en) 2019-01-30
CN109562063A (en) 2019-04-02
KR20190026748A (en) 2019-03-13
WO2017211917A1 (en) 2017-12-14
US20170348394A1 (en) 2017-12-07
US20170348395A1 (en) 2017-12-07
KR20190025905A (en) 2019-03-12
MX2018015070A (en) 2019-05-09
BR112018075259A2 (en) 2019-03-12
AU2017277589A1 (en) 2019-01-24
BR112018075250A2 (en) 2019-03-12

Similar Documents

Publication Publication Date Title
SG11201810901VA (en) Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid
SA518400596B1 (en) Injectable Solution at PH 7 Comprising at Least One Basal Insulin The PI of Which is from 5.8 to 8.5, A Prandial Insulin and/or A Gastrointestinal Hormone, and A Co-Polyamino Acid Bearing Carboxylate
PH12020550828A1 (en) Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
PH12020550827A1 (en) Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
WO2019110797A8 (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
MX2017015579A (en) Solid dosage forms of palbociclib.
PH12018502714A1 (en) Nicotine particles and compositions
EA201890767A1 (en) C4-MODIFIED OLEANOLIC ACID DERIVATIVES FOR INHIBITION OF IL-17 AND OTHER APPLICATIONS
PH12017501486A1 (en) Nasal powder formulation for treatment of hypoglycemia
IL272141A (en) Compositions in the form of an injectable aqueous solution comprising at least human insulin a21g and a prandial action glucagon suppressor
MX2016005395A (en) Stable formulation of insulin glulisine.
MY174991A (en) Eurycoma longifolia extract and its use in enhancing and/or stimulating immune system
PH12020550804A1 (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
MX2019005855A (en) Powderous formulations.
PH12017502319A1 (en) Injectable pharmaceutical formulations of lefamulin
SG11202005320VA (en) Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
MX2016004328A (en) Immunopotentiator.
EP4279577A3 (en) Process
MX2020006670A (en) Aqueous composition comprising 2-(dimethyl-1h-pyrazole-1-yl) succinic acid and ammonia.
MY187571A (en) Krill oil preparations with optimal mineral and metal composition, low impurities and low and stable tma levels
PH12019501946A1 (en) Liquid composition containing pradofloxacin
EP3777887A4 (en) Allergenic action enhancer comprising hyaluronic acid as active ingredient
EP3426043A4 (en) Herbal formulation to raise the human body's ph level from one that is acidic to one that is more alkaline